BR112013015085A8 - Composição farmacêutica, método para preparar uma composição, e, uso de composição - Google Patents
Composição farmacêutica, método para preparar uma composição, e, uso de composiçãoInfo
- Publication number
- BR112013015085A8 BR112013015085A8 BR112013015085A BR112013015085A BR112013015085A8 BR 112013015085 A8 BR112013015085 A8 BR 112013015085A8 BR 112013015085 A BR112013015085 A BR 112013015085A BR 112013015085 A BR112013015085 A BR 112013015085A BR 112013015085 A8 BR112013015085 A8 BR 112013015085A8
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- water
- azole
- preparing
- infusion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 239000002904 solvent Substances 0.000 abstract 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 150000003851 azoles Chemical class 0.000 abstract 1
- 235000019445 benzyl alcohol Nutrition 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- -1 ethanol Chemical compound 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 239000003978 infusion fluid Substances 0.000 abstract 1
- 229960004130 itraconazole Drugs 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 abstract 1
- 229960001589 posaconazole Drugs 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 150000003852 triazoles Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42393710P | 2010-12-16 | 2010-12-16 | |
| US201161509154P | 2011-07-19 | 2011-07-19 | |
| PCT/US2011/065422 WO2012083138A2 (en) | 2010-12-16 | 2011-12-16 | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013015085A2 BR112013015085A2 (pt) | 2016-08-09 |
| BR112013015085A8 true BR112013015085A8 (pt) | 2018-04-03 |
Family
ID=46245384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013015085A BR112013015085A8 (pt) | 2010-12-16 | 2011-12-16 | Composição farmacêutica, método para preparar uma composição, e, uso de composição |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10307418B2 (enExample) |
| EP (1) | EP2651450B1 (enExample) |
| JP (2) | JP6086539B2 (enExample) |
| CN (1) | CN103402543B (enExample) |
| AU (1) | AU2011343576B2 (enExample) |
| BR (1) | BR112013015085A8 (enExample) |
| CA (1) | CA2821823C (enExample) |
| DK (1) | DK2651450T3 (enExample) |
| ES (1) | ES2565353T3 (enExample) |
| HU (1) | HUE028667T2 (enExample) |
| IL (1) | IL226977A (enExample) |
| MX (1) | MX337364B (enExample) |
| NZ (1) | NZ613167A (enExample) |
| RU (2) | RU2734128C2 (enExample) |
| WO (1) | WO2012083138A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2651450B1 (en) * | 2010-12-16 | 2015-12-16 | Borje S. Andersson | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
| CN107970209B (zh) * | 2011-04-28 | 2020-10-30 | 普拉福姆五金器具第二有限公司 | 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法 |
| MX2015003579A (es) * | 2012-12-28 | 2015-06-22 | Suntory Holdings Ltd | Bebida no alcoholica con sabor de cerveza, que tiene estabilidad en el sabor. |
| CN105394045B (zh) * | 2014-09-04 | 2020-02-14 | 中国科学院上海巴斯德研究所 | 一种肠道病毒的小分子化合物抑制剂及其应用 |
| CN105943500B (zh) * | 2016-07-08 | 2019-01-04 | 河南省立眼科医院 | 一种含有艾沙康唑的眼用纳米胶束抗真菌溶液 |
| TWI834808B (zh) | 2019-02-19 | 2024-03-11 | 西班牙商薩爾瓦特實驗室有限公司 | 以單劑包裝的克氯黴唑液體組成物 |
| CN111665301A (zh) * | 2020-05-29 | 2020-09-15 | 南京品生医疗科技有限公司 | 超高效液相色谱串联质谱技术检测血清中抗真菌药物的试剂盒 |
| KR20230109655A (ko) * | 2020-11-16 | 2023-07-20 | 더블유.엘. 고어 앤드 어소시에이트스, 인코포레이티드 | 흐림점이 없는 사전 충전 다회 투여 주입 디바이스, 방법 및 제형 |
| CN113671086B (zh) * | 2021-08-31 | 2023-06-16 | 重庆华邦制药有限公司 | 分离、测定泊沙康唑z2及其杂质的方法 |
| CN114660200A (zh) * | 2022-03-29 | 2022-06-24 | 中国人民解放军总医院 | 一种高效液相色谱串联质谱技术同时测定血浆中4种三唑类抗真菌药物的方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912124A (en) | 1984-02-23 | 1990-03-27 | Ortho Pharmaceutical Corporation | Antifungal dermatological solution |
| DE3702105A1 (de) | 1987-01-24 | 1988-08-04 | Bayer Ag | Parenterale loesung |
| JPH01242525A (ja) | 1988-03-25 | 1989-09-27 | Nippon Nohyaku Co Ltd | 抗真菌外用剤 |
| PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| TW349870B (en) * | 1993-09-30 | 1999-01-11 | Janssen Pharmaceutica Nv | An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof |
| KR0159730B1 (ko) * | 1996-01-15 | 1998-12-01 | 손경식 | 케토코나졸 수성 제제 |
| US7179475B1 (en) * | 1998-12-04 | 2007-02-20 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
| US6362172B2 (en) * | 2000-01-20 | 2002-03-26 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
| GB2365770B (en) | 2000-08-18 | 2002-07-31 | Diomed Dev Ltd | Antifungal ketoconazole composition for topical use |
| US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
| US20050048126A1 (en) * | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| JP2002322056A (ja) | 2001-04-27 | 2002-11-08 | Nippon Kayaku Co Ltd | トリアゾール誘導体の溶液製剤 |
| JP4263441B2 (ja) * | 2002-08-07 | 2009-05-13 | 富士重工業株式会社 | ４輪駆動車の制御装置 |
| AU2003249510A1 (en) | 2002-08-12 | 2004-02-25 | Ranbaxy Laboratories Limited | A parenteral dosage form of selective cox-2 inhibitors |
| ZA200409537B (en) * | 2003-01-31 | 2006-10-25 | Yamanouchi Pharma Co Ltd | Stable solid medicinal composition for oral administration |
| US20060003654A1 (en) * | 2004-06-30 | 2006-01-05 | Lostocco Michael R | Dispersible alcohol/cleaning wipes via topical or wet-end application of acrylamide or vinylamide/amine polymers |
| EP1863481A1 (en) | 2005-03-31 | 2007-12-12 | Brystol-Myers Squibb Company | Methods for administering ixabepilone |
| WO2007002761A2 (en) | 2005-06-27 | 2007-01-04 | Barrier Therapeutics, Inc. | Micogel topical formulations |
| US20070082870A1 (en) | 2005-10-11 | 2007-04-12 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| AU2007355106A1 (en) * | 2006-11-29 | 2008-12-18 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
| EP2191826B1 (en) | 2007-09-05 | 2017-03-08 | Pola Pharma Inc. | Pharmaceutical composition |
| US20090253712A1 (en) | 2008-04-03 | 2009-10-08 | Semmelweis Egyetem | Aqueous solvent system for solubilization of azole compounds |
| WO2009139925A1 (en) * | 2008-05-16 | 2009-11-19 | Panacea Pharmaceuticals, Inc. | Methods for the treatment of brain edema |
| PE20120326A1 (es) | 2009-02-05 | 2012-04-20 | Targeted Delivery Technologies Ltd | Formulaciones farmaceuticas para reducir la proliferacion y viabilidad de los agentes microbianos |
| EP2416757A2 (en) | 2009-04-09 | 2012-02-15 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| EP2651450B1 (en) * | 2010-12-16 | 2015-12-16 | Borje S. Andersson | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
| CN107970209B (zh) * | 2011-04-28 | 2020-10-30 | 普拉福姆五金器具第二有限公司 | 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法 |
-
2011
- 2011-12-16 EP EP11849408.7A patent/EP2651450B1/en not_active Not-in-force
- 2011-12-16 WO PCT/US2011/065422 patent/WO2012083138A2/en not_active Ceased
- 2011-12-16 AU AU2011343576A patent/AU2011343576B2/en not_active Ceased
- 2011-12-16 CA CA2821823A patent/CA2821823C/en not_active Expired - Fee Related
- 2011-12-16 JP JP2013544816A patent/JP6086539B2/ja not_active Expired - Fee Related
- 2011-12-16 US US13/994,152 patent/US10307418B2/en active Active
- 2011-12-16 CN CN201180067824.5A patent/CN103402543B/zh not_active Expired - Fee Related
- 2011-12-16 RU RU2016149770A patent/RU2734128C2/ru active
- 2011-12-16 NZ NZ613167A patent/NZ613167A/en not_active IP Right Cessation
- 2011-12-16 HU HUE11849408A patent/HUE028667T2/en unknown
- 2011-12-16 ES ES11849408.7T patent/ES2565353T3/es active Active
- 2011-12-16 BR BR112013015085A patent/BR112013015085A8/pt active Search and Examination
- 2011-12-16 MX MX2013006816A patent/MX337364B/es active IP Right Grant
- 2011-12-16 DK DK11849408.7T patent/DK2651450T3/en active
- 2011-12-16 RU RU2013132703A patent/RU2618456C2/ru not_active IP Right Cessation
-
2013
- 2013-06-16 IL IL226977A patent/IL226977A/en active IP Right Grant
-
2017
- 2017-01-27 JP JP2017013634A patent/JP6529527B2/ja not_active Expired - Fee Related
-
2019
- 2019-04-16 US US16/385,293 patent/US20190240216A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2651450A4 (en) | 2014-07-09 |
| DK2651450T3 (en) | 2016-03-14 |
| US20140031366A1 (en) | 2014-01-30 |
| RU2618456C2 (ru) | 2017-05-03 |
| WO2012083138A2 (en) | 2012-06-21 |
| JP6529527B2 (ja) | 2019-06-12 |
| AU2011343576B2 (en) | 2016-09-08 |
| CN103402543A (zh) | 2013-11-20 |
| RU2016149770A (ru) | 2018-11-05 |
| HUE028667T2 (en) | 2016-12-28 |
| RU2013132703A (ru) | 2015-01-27 |
| RU2734128C2 (ru) | 2020-10-13 |
| HK1190643A1 (zh) | 2014-07-11 |
| ES2565353T3 (es) | 2016-04-04 |
| EP2651450A2 (en) | 2013-10-23 |
| US20190240216A1 (en) | 2019-08-08 |
| MX337364B (es) | 2016-02-29 |
| US10307418B2 (en) | 2019-06-04 |
| CN103402543B (zh) | 2015-09-16 |
| CA2821823A1 (en) | 2012-06-21 |
| AU2011343576A1 (en) | 2013-07-11 |
| RU2016149770A3 (enExample) | 2020-02-04 |
| CA2821823C (en) | 2019-05-07 |
| WO2012083138A3 (en) | 2012-11-01 |
| JP2013545819A (ja) | 2013-12-26 |
| JP6086539B2 (ja) | 2017-03-01 |
| EP2651450B1 (en) | 2015-12-16 |
| NZ613167A (en) | 2015-09-25 |
| IL226977A (en) | 2017-01-31 |
| BR112013015085A2 (pt) | 2016-08-09 |
| MX2013006816A (es) | 2013-11-01 |
| JP2017114869A (ja) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013015085A8 (pt) | Composição farmacêutica, método para preparar uma composição, e, uso de composição | |
| Roness et al. | Ovarian follicle burnout: a universal phenomenon? | |
| CL2019003433A1 (es) | Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de receptor tirosina quinasa (rtk), o un inhibidor de la angiogénesis, y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014). | |
| JP2012505171A5 (enExample) | ||
| Veraldi | Isoconazole nitrate: a unique broad‐spectrum antimicrobial azole effective in the treatment of dermatomycoses, both as monotherapy and in combination with corticosteroids | |
| CL2011002053A1 (es) | Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel. | |
| CO2021000174A2 (es) | Composiciones tópicas para el alivio del dolor | |
| MX2011012143A (es) | Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas. | |
| CL2011002634A1 (es) | Disolucion acuosa sin alcohol etilico que comprende propanolol o una sal farmaceuticamente aceptable del mismo, un edulcorante tipo no azucarado y menos del 0,01 % (p/v) de un agente conservante; procedimiento de preparacion; uso de la disolucion en el tratamiento de hemangiomas. | |
| PE20041024A1 (es) | Sistema de liberacion controlada | |
| MX2024000828A (es) | Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis. | |
| JP2016514121A (ja) | 真菌感染の処置のための医薬組成物 | |
| AR065317A1 (es) | Uso de quitosanos, derivados de quitosanos y una sal fisiologicamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales | |
| WO2015081904A3 (en) | Polyurethaneurea solutions for compositions with active ingredients or fragrances | |
| JP2020504178A5 (enExample) | ||
| US20120115812A1 (en) | Surface coatings for skin | |
| UY37497A (es) | Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida | |
| AR055591A1 (es) | Una composicion topica protectora de la piel y su uso | |
| PT1879654E (pt) | Combinação farmacêutica que compreende um agente antifúngico e uma substância ativa selecionada especialmente entre eugenol e carvacrol | |
| CN102088859A (zh) | 抗微生物组合物 | |
| JP6427666B2 (ja) | Ｆｋ５０６誘導体を含有するクリプトコッカス属カビ及びカンジダ属カビによる真菌感染を治療するための薬剤学的組成物及びその用途 ｛ｐｈａｒｍａｃｅｕｔｉｃａｌ ｃｏｍｐｏｓｉｔｉｏｎ ｃｏｎｔａｉｎｉｎｇ ｆｋ５０６ ｄｅｒｉｖａｔｉｖｅ ｆｏｒ ｔｒｅａｔｉｎｇ ｆｕｎｇａｌ ｉｎｆｅｃｔｉｏｎ ｃａｕｓｅｄ ｂｙ ｇｅｎｕｓ ｃｒｙｐｔｏｃｏｃｃｕｓ ａｎｄ ｇｅｎｕｓ ｃａｎｄｉｄａ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝ | |
| CN111228260A (zh) | 一种包含雷帕霉素的组合物及其用途 | |
| ES2960745T3 (es) | Composiciones contra infecciones por cándida | |
| CN105411998B (zh) | 含有五味子乙素的治疗烧烫伤的外用组合物 | |
| RU2014101705A (ru) | Пленкообразующая композиция и ее применение для лечения герпеса |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/496 (2006.01), A61K 9/00 (2006.01), A61K 4 |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: BORJE S. ANDERSSON, JEFFREY TARRAND E BENIGNO C. V |
|
| B25A | Requested transfer of rights approved |
Owner name: PLATFORM BRIGHTWORKS TWO, LTD. (US) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |